Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription.
Pannus P, Rutsaert S, De Wit S, Allard SD, Vanham G, Cole B, Nescoi C, Aerts J, De Spiegelaere W, Tsoumanis A, Couttenye MM, Herssens N, De Scheerder MA, Vandekerckhove L, Florence E. Pannus P, et al. Among authors: allard sd. J Int AIDS Soc. 2020 Feb;23(2):e25453. doi: 10.1002/jia2.25453. J Int AIDS Soc. 2020. PMID: 32107887 Free PMC article.
Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWH.
Laeremans T, D'haese S, Aernout J, Barbé K, Pannus P, Rutsaert S, Vancutsem E, Vanham G, Necsoi C, Spiegelaere W, Couttenye M, Herssens N, Scheerder MA, Wit S, Vandekerckhove L, Florence E, Aerts JL, Allard SD. Laeremans T, et al. Among authors: allard sd. AIDS. 2022 Nov 1;36(13):1761-1768. doi: 10.1097/QAD.0000000000003352. Epub 2022 Aug 10. AIDS. 2022. PMID: 36172869
Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.
Libois A, Florence E, Derdelinckx I, Yombi JC, Henrard S, Uurlings F, Vandecasteele S, Allard SD, Demeester R, Van Wanzeele F, Ausselet N, De Wit S. Libois A, et al. Among authors: allard sd. Acta Clin Belg. 2018 Aug;73(4):275-280. doi: 10.1080/17843286.2018.1428506. Epub 2018 Feb 12. Acta Clin Belg. 2018. PMID: 29429390
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R, Yombi JC, Darcis G, Florence E, Allard SD, De Scheerder MA, Henrard S, Demeester R, Messiaen P, Ausselet N, Loeckx M, Delforge M, De Wit S; Belgian Research on AIDS and HIV Consortium (BREACH). Nasreddine R, et al. Among authors: allard sd. HIV Med. 2023 Mar;24(3):267-278. doi: 10.1111/hiv.13373. Epub 2022 Aug 8. HIV Med. 2023. PMID: 35938381
A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.
Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandeloo J, Pistoor F, Heirman C, Beyer WE, Eilers PH, Corthals J, Padmos I, Thielemans K, Osterhaus AD, Lacor P, van der Ende ME, Aerts JL, van Baalen CA, Gruters RA. Allard SD, et al. Clin Immunol. 2012 Mar;142(3):252-68. doi: 10.1016/j.clim.2011.10.010. Epub 2011 Nov 16. Clin Immunol. 2012. PMID: 22177848 Clinical Trial.
DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.
de Goede AL, Andeweg AC, van den Ham HJ, Bijl MA, Zaaraoui-Boutahar F, van IJcken WF, Wilgenhof S, Aerts JL, Gruters RA, Osterhaus AD; DC-TRN trial investigators. de Goede AL, et al. Vaccine. 2015 Jun 9;33(25):2922-9. doi: 10.1016/j.vaccine.2015.04.047. Epub 2015 Apr 24. Vaccine. 2015. PMID: 25913415 Clinical Trial.
53 results